Cargando…
Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended. METHODS: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 2...
Autores principales: | Xu, Yonghao, Li, Manshu, Zhou, Liang, Liu, Dongdong, He, Weiqun, Liang, Weibo, Sun, Qingwen, Sun, Huadong, Li, Yimin, Liu, Xiaoqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672023/ https://www.ncbi.nlm.nih.gov/pubmed/34916812 http://dx.doi.org/10.2147/IDR.S330743 |
Ejemplares similares
-
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015) -
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015) -
Characteristics of chronically critically ill patients: comparing two definitions
por: Boniatti, Márcio Manozzo, et al.
Publicado: (2011) -
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
por: Leroy, Vincent, et al.
Publicado: (2016) -
Real‐time echocardiographic guidance for confirming septal placement of right ventricular leads: A pilot study
por: Yan, Manshu, et al.
Publicado: (2021)